Pilot corpus: NIH-funded biomedical datasets. Any DOI can be scored on demand — network effects sharpen as coverage grows.

Effectiveness of a Third Dose of Pfizer-BioNTech and Moderna Vaccines in Preventing COVID-19 Hospitalization Among Immunocompetent and Immunocompromised Adults — United States, August–December 2021

MMWR Morbidity and Mortality Weekly Report(2022)10.15585/mmwr.mm7104a2Source: DataRank Database

Effectiveness of a Third Dose of Pfizer-BioNTech and Moderna Vaccines in Preventing COVID-19 Hospitalization Among Immunocompetent and Immunocompromised Adults — United States, August–December 2021 is a research paper published in MMWR Morbidity and Mortality Weekly Report (2022). On theSindex it has a DataRank of 0. It has been cited 100 times.

N/A

0DataRank · unranked

Scored on demand from live citation data

Open Access100 citations

Download PDF

Cite:

DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?

›Methodology & internals

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Pipeline:MetadataData-paper checkEnrichmentCitation networkScoring

Enrichment:Funding (3 grants)Impact (FWCI 9.57)OA: goldTopics (50)IDs (PubMed, PMC, OpenAlex)SDGs (1)

FAIR Checklist

Context only (not used in score)

Findable (1/2)

Has DOI

Accessible (1/2)

Open Access

Interoperable (0/2)

Reusable (0/3)

FAIR checklist signals are shown for context only and do not affect DataRank scoring.

Run a calibrated FAIR evaluation for this paper →

We only score data papers we can read in full — never from an abstract alone.

Authors (99)

Manish M. Patel ORCID,Manjusha Gaglani ORCID,Adit A. Ginde ORCID,David J. Douin ORCID,H. Keipp Talbot ORCID

Live enrichment

PubMed:35085218 PMC:PMC9351530 OpenAlex:https://openalex.org/W4210747912

NIGMS NIH HHS

Grant: T32 GM135169

NHLBI NIH HHS

Grant: T32 HL087738

NIGMS NIH HHS

Grant: K23 GM129661

FWCI

9.57

Citation Percentile

1.0%

Citation Trend

2022

2023

2024

2025

2026

goldLicense: public-domain

journalhttps://www.cdc.gov/mmwr/volumes/71/wr/pdfs/mm7104a2-H.pdf

publisherhttps://www.cdc.gov/mmwr/volumes/71/wr/pdfs/mm7104a2-H.pdf

journalhttps://doi.org/10.15585/mmwr.mm7104a2

repositoryhttps://pubmed.ncbi.nlm.nih.gov/35085218

repositoryhttps://www.ncbi.nlm.nih.gov/pmc/articles/9351530

Fields of Study

SARS-CoV-2 and COVID-19 ResearchVaccine Coverage and HesitancyCOVID-19 Clinical Research Studies2019-nCoV Vaccine mRNA-1273AdultAgedBNT162 VaccineCOVID-19FemaleHospitalizationHumansImmunization, SecondaryImmunocompetenceImmunocompromised HostMaleMiddle AgedSARS-CoV-2United StatesVaccine Efficacy

MeSH Terms

COVID-19SARS-CoV-2Vaccine EfficacyBNT162 Vaccine2019-nCoV Vaccine mRNA-1273AdultAgedFemaleHospitalizationHumansImmunization, SecondaryImmunocompetenceMaleMiddle AgedUnited StatesImmunocompromised Host

Keywords

MedicineBooster doseCoronavirus disease 2019 (COVID-19)PediatricsVaccinationBooster (rocketry)Young adultAuthorizationSevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2)Internal medicineVirologyVirusInfectious disease (medical specialty)TiterDisease

Sustainable Development Goals

SDG 0: Good health and well-being